Compare AAME & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | JSPR |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 43.7M |
| IPO Year | N/A | N/A |
| Metric | AAME | JSPR |
|---|---|---|
| Price | $2.78 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.13 |
| AVG Volume (30 Days) | 19.5K | ★ 975.8K |
| Earning Date | 11-14-2025 | 02-26-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ 11.99 | N/A |
| 52 Week Low | $1.25 | $1.39 |
| 52 Week High | $3.71 | $7.19 |
| Indicator | AAME | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 43.79 |
| Support Level | $2.67 | $1.51 |
| Resistance Level | $2.80 | $1.66 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 27.76 | 45.16 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.